We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include Clarivate, Expedia Group and Haemonetics
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 25, 2023 – Stocks in this week’s article are Clarivate Plc (CLVT - Free Report) , Expedia Group (EXPE - Free Report) and Haemonetics Corp. (HAE - Free Report) .
Time to Pick Up These 3 Top Relative Price Strength Stocks
We know that the market witnessed a broad-based decline in 2022 owing to a high-interest-rate regime and tighter monetary control adopted by the Fed to combat a 40-year high inflation. But as we have entered 2023, a very early sign of a rebound is visible on Wall Street, with peak inflation seemingly behind us. As proof of this, the S&P 500 — which tracks the biggest U.S.-listed companies — has crept above 4K for the first time in several weeks.
In particular, the market participants see a pending 25 basis-point interest rate hike next week as a sign of slowing Fed tightening, providing a much-needed respite to the economy. Yet, despite the central bank's softening stance, traders and investors continue to see headwinds in the form of softness in consumer spending, worries over a tight labor market and disappointing fourth-quarter 2022 earnings numbers. As such, extremely volatile trading in U.S. markets is expected to continue for some time.
In the current jittery market environment, investors who might want to stay exposed to the equity setup should focus on good investment opportunities. One of the ways such potential plays could be identified is to look for signs of relative price strength.
Relative Price Strength Strategy
Investors generally gauge a stock's potential returns by examining earnings growth and valuation multiples. At the same time, it's essential to measure the performance of such a stock relative to its industry or peers, or an appropriate benchmark.
If you see that a stock is underperforming on fundamental factors, it would be prudent to move on and find a better alternative. However, those outperforming their respective sectors in terms of price should be selected because they stand a better chance of providing considerable returns.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months at least and having solid fundamentals indicate room for growth and are the best ways to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter's (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Here are the three stocks that made it through the screen:
Clarivate Plc: The company provides information and analytic products worldwide, including scientific, patient and academic research to the top pharmaceutical firms. The 2022 Zacks Consensus Estimate for this London-based firm indicates 12.5% year-over-year earnings per share growth. CLVT has a VGM Score of B.
Clarivate beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 9.4%, on average. CLVT shares have lost 33.6% in a year.
Expedia Group: One of the largest online travel companies in the world, Expedia Group's web portals focus on travel planning, travel purchases and travel experience sharing. The 2022 Zacks Consensus Estimate for the Seattle, WA-based company indicates 350.9% year-over-year earnings per share growth. EXPE has a VGM Score of A.
Expedia Group beat the Zacks Consensus Estimate for earnings in three of the last four quarters. Over the past 90 days, the company saw the Zacks Consensus Estimate for 2022 move up 4.8%. EXPE stock has lost 32.5% in a year.
Haemonetics Corp.: The company provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The fiscal 2023 Zacks Consensus Estimate for this Boston, MA-based firm indicates 11.2% year-over-year earnings per share growth. HAE has a VGM Score of A.
Haemonetics beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 12.1%, on average. HAE shares have surged 79.9% in a year.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include Clarivate, Expedia Group and Haemonetics
For Immediate Release
Chicago, IL – January 25, 2023 – Stocks in this week’s article are Clarivate Plc (CLVT - Free Report) , Expedia Group (EXPE - Free Report) and Haemonetics Corp. (HAE - Free Report) .
Time to Pick Up These 3 Top Relative Price Strength Stocks
We know that the market witnessed a broad-based decline in 2022 owing to a high-interest-rate regime and tighter monetary control adopted by the Fed to combat a 40-year high inflation. But as we have entered 2023, a very early sign of a rebound is visible on Wall Street, with peak inflation seemingly behind us. As proof of this, the S&P 500 — which tracks the biggest U.S.-listed companies — has crept above 4K for the first time in several weeks.
In particular, the market participants see a pending 25 basis-point interest rate hike next week as a sign of slowing Fed tightening, providing a much-needed respite to the economy. Yet, despite the central bank's softening stance, traders and investors continue to see headwinds in the form of softness in consumer spending, worries over a tight labor market and disappointing fourth-quarter 2022 earnings numbers. As such, extremely volatile trading in U.S. markets is expected to continue for some time.
In the current jittery market environment, investors who might want to stay exposed to the equity setup should focus on good investment opportunities. One of the ways such potential plays could be identified is to look for signs of relative price strength.
Relative Price Strength Strategy
Investors generally gauge a stock's potential returns by examining earnings growth and valuation multiples. At the same time, it's essential to measure the performance of such a stock relative to its industry or peers, or an appropriate benchmark.
If you see that a stock is underperforming on fundamental factors, it would be prudent to move on and find a better alternative. However, those outperforming their respective sectors in terms of price should be selected because they stand a better chance of providing considerable returns.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months at least and having solid fundamentals indicate room for growth and are the best ways to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter's (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Here are the three stocks that made it through the screen:
Clarivate Plc: The company provides information and analytic products worldwide, including scientific, patient and academic research to the top pharmaceutical firms. The 2022 Zacks Consensus Estimate for this London-based firm indicates 12.5% year-over-year earnings per share growth. CLVT has a VGM Score of B.
Clarivate beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 9.4%, on average. CLVT shares have lost 33.6% in a year.
Expedia Group: One of the largest online travel companies in the world, Expedia Group's web portals focus on travel planning, travel purchases and travel experience sharing. The 2022 Zacks Consensus Estimate for the Seattle, WA-based company indicates 350.9% year-over-year earnings per share growth. EXPE has a VGM Score of A.
Expedia Group beat the Zacks Consensus Estimate for earnings in three of the last four quarters. Over the past 90 days, the company saw the Zacks Consensus Estimate for 2022 move up 4.8%. EXPE stock has lost 32.5% in a year.
Haemonetics Corp.: The company provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The fiscal 2023 Zacks Consensus Estimate for this Boston, MA-based firm indicates 11.2% year-over-year earnings per share growth. HAE has a VGM Score of A.
Haemonetics beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 12.1%, on average. HAE shares have surged 79.9% in a year.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2043112/time-to-pick-these-3-top-relative-price-strength-stocks
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.